Stephenson Harwood advises on $25 million funding in ViaNautis Bio
Stephenson Harwood LLP has advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.
ViaNautis, formerly known as SomaServe, has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
The raise was led by UCB Ventures, BGF and 4Bio Capital, and additional participation was provided by the Cystic Fibrosis Foundation, Eli Lilly and Company, as well as existing investors including Origin Capital, Meltwind and O2H. The proceeds from the round will be used to fuel the rapid development of products using the polyNaut® platform, expand the scientific and management teams and establish industry-leading laboratory facilities. ViaNautis' proprietary drug delivery platform is designed to deliver genetic therapeutic payloads to the specific site of action.
The Stephenson Harwood team comprised of corporate partner Anthony Clare and corporate associates Michelle Gomes and Yuki Yue, with further assistance provided by IP partner Naomi Leach and associate Ainsleigh Stone.
分享文章
相关专业知识
相关文章
The cybersecurity wave hitting life sciences and healthcare companies: what you need to know
Pro bono where it matters
Are we moving towards a more permissive UK framework for life sciences research data?
MHRA consults on draft regulatory framework for rare disease therapies
Life Sciences A to Z - S is for Safe Harbour: What you need to know about the UK's new Technology Transfer Block Exemption
Life Sciences A to Z - R is for Rare Diseases in the UK: An Overview of the Regulatory and Policy Landscape
Partner Paul Inman joins Stephenson Harwood
The European Data Protection Board Releases New Guidelines on the Processing of Personal Data for Scientific Research
FDA and EMA jointly issue guiding principles of good AI practice in drug development
